Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Transthoracic fine-needle aspiration diagnosis of solid, subsolid, and partially calcified lung nodules: A retrospective study from a single academic center.

Zhou Y, Gong G, Wang H, Habibabady ZA, Lang P, Hales R, Askin F, Gabrielson E, Li QK.

Cytojournal. 2019 Aug 22;16:16. doi: 10.4103/cytojournal.cytojournal_43_18. eCollection 2019.

2.

DNA Methylation Markers for Breast Cancer Detection in the Developing World.

Downs B, Mercado-Rodriguez C, Cimino-Mathews A, Chen C, Yuan J, Van Den Berg EJ, Cope L, Schmitt F, Tse GM, Ali SZ, Meir-Levi D, Sood R, Li J, Richardson AL, Mosunjac M, Rizzo M, Tulac S, Kocmond K, de Guzman TN, Lai EW, Rhees B, Bates M, Wolff AC, Gabrielson E, Harvey S, Umbricht CB, Visvanathan K, Fackler MJ, Sukumar S.

Clin Cancer Res. 2019 Jul 12. pii: clincanres.3277.2018. doi: 10.1158/1078-0432.CCR-18-3277. [Epub ahead of print]

PMID:
31300453
3.

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.

Jafarnejad M, Gong C, Gabrielson E, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Popel AS.

AAPS J. 2019 Jun 24;21(5):79. doi: 10.1208/s12248-019-0350-x.

4.

Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

Zhou Y, Höti N, Ao M, Zhang Z, Zhu H, Li L, Askin F, Gabrielson E, Zhang H, Li QK.

Biomark Med. 2019 Jun;13(9):761-771. doi: 10.2217/bmm-2018-0441. Epub 2019 Jun 3.

PMID:
31157548
5.

Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer.

Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, Antonio MJ, Camelo F, Li T, Nguyen S, Hoang G, Nguyen K, Udupa S, Sazeides C, Shen YA, Elgogary A, Reyes J, Zhao L, Kleensang A, Chaichana KL, Hartung T, Betenbaugh MJ, Marie SK, Jung JG, Wang TL, Gabrielson E, Le A.

Cell Rep. 2019 Apr 9;27(2):491-501.e6. doi: 10.1016/j.celrep.2019.03.036.

6.

Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells.

Muniraj N, Siddharth S, Nagalingam A, Walker A, Woo J, Gyorffy B, Gabrielson E, Saxena NK, Sharma D.

Carcinogenesis. 2019 Jan 29. doi: 10.1093/carcin/bgz015. [Epub ahead of print]

PMID:
30698683
7.

Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer.

Sugimoto K, Ito T, Woo J, Tully E, Sato K, Orita H, Brock MV, Gabrielson E.

J Surg Res. 2019 Mar;235:479-486. doi: 10.1016/j.jss.2018.10.032. Epub 2018 Nov 26.

PMID:
30691832
8.

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE.

Cancer Res. 2019 Mar 15;79(6):1214-1225. doi: 10.1158/0008-5472.CAN-18-1127. Epub 2018 Dec 12.

9.

Correction to: Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts.

Wu X, Zahari MS, Renuse S, Sahasrabuddhe NA, Chaerkady R, Kim MS, Fackler MJ, Stampfer M, Gabrielson E, Sukumar S, Pandey A.

Clin Proteomics. 2018 Nov 17;15:37. doi: 10.1186/s12014-018-9210-4. eCollection 2018.

10.

Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S.

J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7.

11.

Detection of RAS and RAS-associated alterations in primary lung adenocarcinomas. A correlation between molecular findings and tumor characteristics.

Shaukat I, Kern JJ, Höti N, Zhang H, Li J, Zheng G, Askin F, Gabrielson E, Li QK.

Hum Pathol. 2019 Feb;84:18-25. doi: 10.1016/j.humpath.2018.09.004. Epub 2018 Sep 25.

PMID:
30266251
12.

C3a is required for ILC2 function in allergic airway inflammation.

Gour N, Smole U, Yong HM, Lewkowich IP, Yao N, Singh A, Gabrielson E, Wills-Karp M, Lajoie S.

Mucosal Immunol. 2018 Nov;11(6):1653-1662. doi: 10.1038/s41385-018-0064-x. Epub 2018 Aug 13.

13.

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).

Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, Rekhtman N, Anders RA, Cuda JD, Illei PB, Gabrielson E, Askin FB, Niknafs N, Smith KN, Velez MJ, Sauter JL, Isbell JM, Jones DR, Battafarano RJ, Yang SC, Danilova L, Wolchok JD, Topalian SL, Velculescu VE, Pardoll DM, Brahmer JR, Hellmann MD, Chaft JE, Cimino-Mathews A, Taube JM.

Ann Oncol. 2018 Aug 1;29(8):1853-1860. doi: 10.1093/annonc/mdy218.

14.

Quantitative phosphoproteomic analysis reveals reciprocal activation of receptor tyrosine kinases between cancer epithelial cells and stromal fibroblasts.

Wu X, Zahari MS, Renuse S, Sahasrabuddhe NA, Chaerkady R, Kim MS, Fackler MJ, Stampfer M, Gabrielson E, Sukumar S, Pandey A.

Clin Proteomics. 2018 Jun 15;15:21. doi: 10.1186/s12014-018-9197-x. eCollection 2018. Erratum in: Clin Proteomics. 2018 Nov 17;15:37.

15.

De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD.

FASEB J. 2018 Jun 15:fj201800204. doi: 10.1096/fj.201800204. [Epub ahead of print]

PMID:
29906244
16.

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM.

N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

17.

Nrf2 signaling and autophagy are complementary in protecting breast cancer cells during glucose deprivation.

Walker A, Singh A, Tully E, Woo J, Le A, Nguyen T, Biswal S, Sharma D, Gabrielson E.

Free Radic Biol Med. 2018 May 20;120:407-413. doi: 10.1016/j.freeradbiomed.2018.04.009. Epub 2018 Apr 9.

18.

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.

Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, Hann CL, Kelly RJ, Coleman B, Gabrielson E, Rosner GL, Ettinger DS.

Oncologist. 2018 Jul;23(7):859-865. doi: 10.1634/theoncologist.2017-0465. Epub 2018 Feb 27.

19.

Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells.

Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F, Semenza GL.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1239-E1248. doi: 10.1073/pnas.1718197115. Epub 2018 Jan 24.

20.

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.

Osmani L, Askin F, Gabrielson E, Li QK.

Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. doi: 10.1016/j.semcancer.2017.11.019. Epub 2017 Nov 26. Review.

21.

Unique pulmonary immunotoxicological effects of urban PM are not recapitulated solely by carbon black, diesel exhaust or coal fly ash.

Gour N, Sudini K, Khalil SM, Rule AM, Lees P, Gabrielson E, Groopman JD, Lajoie S, Singh A.

Environ Res. 2018 Feb;161:304-313. doi: 10.1016/j.envres.2017.10.041. Epub 2017 Nov 24.

22.

Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.

Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, Gabrielson EW, Stearns V, Sukumar S.

Breast Cancer Res Treat. 2018 Jan;167(1):107-116. doi: 10.1007/s10549-017-4503-2. Epub 2017 Sep 16.

23.

Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations.

Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O'Hagan HM, Murphy L, Zahnow CA, Gabrielson E, Velculescu VE, Easwaran HP, Baylin SB.

Cancer Cell. 2017 Sep 11;32(3):360-376.e6. doi: 10.1016/j.ccell.2017.08.006.

24.

Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study.

Huang P, Park S, Yan R, Lee J, Chu LC, Lin CT, Hussien A, Rathmell J, Thomas B, Chen C, Hales R, Ettinger DS, Brock M, Hu P, Fishman EK, Gabrielson E, Lam S.

Radiology. 2018 Jan;286(1):286-295. doi: 10.1148/radiol.2017162725. Epub 2017 Sep 5.

25.

ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.

Chung SJ, Nagaraju GP, Nagalingam A, Muniraj N, Kuppusamy P, Walker A, Woo J, Győrffy B, Gabrielson E, Saxena NK, Sharma D.

Autophagy. 2017 Aug 3;13(8):1386-1403. doi: 10.1080/15548627.2017.1332565. Epub 2017 Jul 11.

26.

The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.

Lilo MT, Allison DB, Younes BK, Cui M, Askin FB, Gabrielson E, Li QK.

Cancer Cytopathol. 2017 Sep;125(9):717-725. doi: 10.1002/cncy.21886. Epub 2017 Jun 13.

27.

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL.

EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19.

28.

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.

Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E.

Mod Pathol. 2017 Apr;30(4):530-538. doi: 10.1038/modpathol.2016.213. Epub 2017 Jan 6.

29.

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.

Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Kang H, Sharfman W, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf RB, Brahmer JR, Karchin R, Pardoll DM, Velculescu VE.

Cancer Discov. 2017 Mar;7(3):264-276. doi: 10.1158/2159-8290.CD-16-0828. Epub 2016 Dec 28.

30.

The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.

Wu X, Zahari MS, Renuse S, Kelkar DS, Barbhuiya MA, Rojas PL, Stearns V, Gabrielson E, Malla P, Sukumar S, Mahajan NP, Pandey A.

Oncotarget. 2017 Jan 10;8(2):2971-2983. doi: 10.18632/oncotarget.13579.

31.

Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.

Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, Nimmagadda S, Sudini K, Brimacombe KR, Gajghate S, Ma J, Wang A, Xu X, Shahane SA, Xia M, Woo J, Mensah GA, Wang Z, Ferrer M, Gabrielson E, Li Z, Rastinejad F, Shen M, Boxer MB, Biswal S.

ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. Epub 2016 Oct 17.

32.

Expression of P40 and P63 in lung cancers using fine needle aspiration cases. Understanding clinical pitfalls and limitations.

Lilo MT, Allison D, Wang Y, Ao M, Gabrielson E, Geddes S, Zhang H, Askin F, Li QK.

J Am Soc Cytopathol. 2016 May-Jun;5(3):123-132.

33.

Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.

Zhang C, Zhi WI, Lu H, Samanta D, Chen I, Gabrielson E, Semenza GL.

Oncotarget. 2016 Oct 4;7(40):64527-64542. doi: 10.18632/oncotarget.11743.

34.

Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.

Hu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, Konstantinopoulos PA, Gabrielson E, Hines-Boykin R, Pihan G, Yuan X, Sotiriou C, Dittmer DP, Fingeroth JD, Wulf GM.

EBioMedicine. 2016 Jul;9:148-160. doi: 10.1016/j.ebiom.2016.05.025. Epub 2016 May 21.

35.

Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.

Sharma R, Wang Y, Chen L, Gurda GT, Geddes S, Gabrielson E, Askin F, Li QK.

Hum Pathol. 2016 Aug;54:8-16. doi: 10.1016/j.humpath.2016.02.027. Epub 2016 Apr 1.

PMID:
27045515
36.

Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.

Allison DB, Lilo MT, Geddes S, Pallavajjalla A, Askin F, Gabrielson E, Zheng G, Li QK.

Cancer Cytopathol. 2016 Jul;124(7):485-92. doi: 10.1002/cncy.21714. Epub 2016 Mar 23.

37.

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.

Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A.

Oncotarget. 2015 Oct 6;6(30):29143-60. doi: 10.18632/oncotarget.5020.

38.

Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.

Wu X, Zahari MS, Renuse S, Nirujogi RS, Kim MS, Manda SS, Stearns V, Gabrielson E, Sukumar S, Pandey A.

Mol Cell Proteomics. 2015 Nov;14(11):2887-900. doi: 10.1074/mcp.M115.050484. Epub 2015 Sep 1.

39.

Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia.

Zahari MS, Wu X, Pinto SM, Nirujogi RS, Kim MS, Fetics B, Philip M, Barnes SR, Godfrey B, Gabrielson E, Nevo E, Pandey A.

Sci Rep. 2015 Sep 2;5:13660. doi: 10.1038/srep13660.

40.

Intraoperative Assessment of Final Margins with a Handheld Optical Imaging Probe During Breast-Conserving Surgery May Reduce the Reoperation Rate: Results of a Multicenter Study.

Zysk AM, Chen K, Gabrielson E, Tafra L, May Gonzalez EA, Canner JK, Schneider EB, Cittadine AJ, Scott Carney P, Boppart SA, Tsuchiya K, Sawyer K, Jacobs LK.

Ann Surg Oncol. 2015 Oct;22(10):3356-62. doi: 10.1245/s10434-015-4665-2. Epub 2015 Jul 23.

41.

AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.

Jhaveri TZ, Woo J, Shang X, Park BH, Gabrielson E.

Oncotarget. 2015 Jun 20;6(17):14754-65.

42.

Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer.

Calmon MF, Jeschke J, Zhang W, Dhir M, Siebenkäs C, Herrera A, Tsai HC, O'Hagan HM, Pappou EP, Hooker CM, Fu T, Schuebel KE, Gabrielson E, Rahal P, Herman JG, Baylin SB, Ahuja N.

Epigenetics. 2015;10(7):622-32. doi: 10.1080/15592294.2015.1050173.

43.

Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.

Gurda GT, Zhang L, Wang Y, Chen L, Geddes S, Cho WC, Askin F, Gabrielson E, Li QK.

Clin Transl Med. 2015 Apr 21;4:16. doi: 10.1186/s40169-015-0057-2. eCollection 2015.

44.

A breast cancer cell microarray (CMA) as a rapid method to characterize candidate biomarkers.

Wu X, Zahari MS, Renuse S, Jacob HK, Sakamuri S, Singal M, Gabrielson E, Sukumar S, Pandey A.

Cancer Biol Ther. 2014;15(12):1593-9. doi: 10.4161/15384047.2014.961886.

45.

TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V.

J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741. Epub 2014 Dec 4.

46.

Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease.

Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL Sr, Gabrielson E, Dewitty RL Jr.

Cancer Genomics Proteomics. 2014 Nov-Dec;11(6):279-94.

PMID:
25422359
47.

Expression of transcript factors SALL4 and OCT4 in a subset of non-small cell lung carcinomas (NSCLC).

Rodriguez E, Chen L, Ao MH, Geddes S, Gabrielson E, Askin F, Zhang H, Li QK.

Transl Respir Med. 2014 Oct 2;2(1):10. doi: 10.1186/s40247-014-0010-7. eCollection 2014 Dec.

48.

Activation of diverse signalling pathways by oncogenic PIK3CA mutations.

Wu X, Renuse S, Sahasrabuddhe NA, Zahari MS, Chaerkady R, Kim MS, Nirujogi RS, Mohseni M, Kumar P, Raju R, Zhong J, Yang J, Neiswinger J, Jeong JS, Newman R, Powers MA, Somani BL, Gabrielson E, Sukumar S, Stearns V, Qian J, Zhu H, Vogelstein B, Park BH, Pandey A.

Nat Commun. 2014 Sep 23;5:4961. doi: 10.1038/ncomms5961.

49.

The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer.

Ao MH, Zhang H, Sakowski L, Sharma R, Illei PB, Gabrielson E, Askin F, Li QK.

Hum Pathol. 2014 May;45(5):926-34. doi: 10.1016/j.humpath.2014.01.005. Epub 2014 Jan 25.

50.

Long interspersed element-1 protein expression is a hallmark of many human cancers.

Rodić N, Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IeM, Duffield AS, Montgomery EA, Gabrielson E, Netto GJ, Lotan TL, De Marzo AM, Westra W, Binder ZA, Orr BA, Gallia GL, Eberhart CG, Boeke JD, Harris CR, Burns KH.

Am J Pathol. 2014 May;184(5):1280-6. doi: 10.1016/j.ajpath.2014.01.007. Epub 2014 Mar 6.

Supplemental Content

Loading ...
Support Center